United States Patent 5,455,044 (US 5,455,044): Scope, Claims, and US Patent Landscape

What does US 5,455,044 claim, in plain technical scope terms?

US 5,455,044 claims a specific treatment method for cell proliferative diseases (broadly framed as “cell proliferative” without naming tumor types) using:

1) Route: intralumbar administration to cerebrospinal fluid (CSF)
2) Drug: a therapeutically effective amount of an antitumor drug
3) Delivery carrier: the antitumor drug is in a synthetic membrane vesicle
4) Retention objective: the formulation is arranged so the antitumor agent persists in the cerebro-ventricular space long enough to ameliorate disease

The claims do not limit the antitumor drug to a single chemical entity; they limit the method by how and where the drug is delivered and the vesicle architecture.

Claim set as provided (independent + dependents)

Claim	Category	Core limitation(s)
1	Independent method claim	Intralumbar administration to CSF of a human with cell proliferative disease; therapeutically effective amount of an antitumor drug in a synthetic membrane vesicle; vesicle causes persistence in cerebro-ventricular space for time sufficient to ameliorate disease
2	Dependent	Synthetic membrane vesicle is a liposome
3	Dependent	Liposome contains multiple concentric chambers
4	Dependent	Synthetic membrane vesicle contains multiple non-concentric chambers

What is the claim construction likely to cover (and what it will exclude)?

1) “Intralumbar administration to CSF” anchors the infringing act to delivery route

Scope centers on intralumbar delivery (lumbar route) into CSF. That wording typically supports enforcement against:

Procedures using lumbar injection into the CSF space with the vesicle formulation
Protocols designed to distribute drug within CSF and into ventricular regions

It likely excludes:

Systemic administration (IV, oral, intramuscular) that does not use intralumbar CSF delivery
Direct intra-parenchymal brain injections unless the act still involves intralumbar administration to CSF and the formulation reaches the cerebro-ventricular space

2) “Synthetic membrane vesicle” is broad: liposomes and chambered vesicles

Claim 1 uses “synthetic membrane vesicle” rather than limiting to liposomes. That gives the claim a platform-like delivery concept.

Dependents narrow:

Claim 2: liposome specifically
Claims 3 and 4: vesicles with multiple chambers, with a geometric distinction:
- Concentric chambers (Claim 3)
- Non-concentric chambers (Claim 4)

This creates two enforceable sub-buckets of vesicle design.

3) “Antitumor drug” is open-ended: ingredient identity not limited

Claim 1 covers “an antitumor drug” without listing agents. That usually means the patent can read on many oncology actives, provided the other structural and route limitations are met.

4) “Persists in the cerebro-ventricular space for a time sufficient” is functional language tied to delivery residence

The functional limitation is central. It is not only that a vesicle is injected into CSF; it is that the antitumor agent persists in the cerebro-ventricular space long enough to ameliorate.

That functional element is typically used to distinguish:

Rapid clearance formulations that do not provide sustained ventricular exposure
Carriers that release too quickly or do not reach/maintain ventricular levels

The patent scope therefore tracks residence time and distribution rather than only “encapsulation.”

How do the dependent claims define additional scope?

Dependent claims create narrower requirements layered on top of Claim 1.

Claim 2 (liposomes)

If the accused formulation is a liposome containing an antitumor drug and is delivered intralumbar to CSF, it can fall under Claim 2 (and also within Claim 1 if all Claim 1 limitations are met).

Claim 3 (multiple concentric chambers)

This narrows to liposomes with multiple concentric chambers. The geometry matters:

“Concentric” suggests nested or ring-like chamber structures sharing a common center axis
The claim does not specify number of chambers, but “multiple” implies at least two discrete chamber regions

Claim 4 (multiple non-concentric chambers)

This alternative narrows to “multiple non-concentric chambers,” which can cover different chamber arrangements not sharing a single common center.

What is the likely novelty and technical focus relative to common prior art patterns?

Even without enumerating specific citations here, the claim language indicates the patent is built around a common clinical problem: CSF and ventricular clearance limiting sustained local exposure for CNS malignancies.

The novelty appears to be the combination of:

CSF intralumbar administration
synthetic vesicle encapsulation
a designed vesicle architecture that supports persistence in cerebro-ventricular space

In patent landscape terms, such claims usually face prior art in two areas: 1) CSF delivery methods (e.g., intrathecal or intralumbar delivery) of antitumor drugs 2) controlled-release or encapsulation approaches using liposomes or vesicles

The differentiator for this patent is the functional ventricular persistence and the synthetic vesicle chamber architecture at least in the dependent claims.

What does this mean for freedom-to-operate (FTO) targeting?

From an enforcement/avoidance perspective, the key infringement “switches” are:

Infringement-sensitive variables

Route: must be intralumbar delivery into CSF
Active: must be an antitumor drug
Carrier: must be a synthetic membrane vesicle (liposome for dependent claim 2)
Design: for claims 3 and 4, multi-chamber architecture with defined concentricity
Outcome: antitumor agent must persist in cerebro-ventricular space for a time sufficient to ameliorate

Likely design-around levers (conceptual, not legal advice)

Change administration route away from intralumbar CSF (for example, non-CSF routes)
Use a non-vesicle delivery mechanism (not a synthetic membrane vesicle)
Use vesicles without multi-chamber architectures (to avoid claims 3 and 4 specifically)
Ensure that the formulation does not achieve “persistence” in cerebro-ventricular space (to attack the functional limitation in Claim 1)

What is the US patent landscape likely to look like around this technology?

A complete landscape requires bibliographic verification and citation mining. Under the constraint of using only the information provided in the prompt, the landscape below is structured as a map of claim-adjacent patent families rather than a list of specific patents.

Patent landscape clusters adjacent to US 5,455,044’s claim themes

Cluster	Claim-adjacent concept	Typical claim language signals
Intrathecal/intralumbar antitumor delivery	CSF route administration	“intralumbar,” “intrathecal,” “CSF,” “cerebroventricular”
Vesicle encapsulation for CNS delivery	Synthetic carriers	“liposome,” “vesicle,” “encapsulated,” “membrane-bound”
Controlled release / residence time	Persistence requirement	“retained,” “prolonged,” “sustained,” “residence,” “release profile”
Multi-compartment / multi-chamber vesicles	Chamber architecture	“multiple chambers,” “concentric,” “non-concentric,” “multi-lamellar”
CNS malignancy treatment concepts	Target disease class	“cell proliferative,” “tumor,” “neoplasm,” “CNS cancer”

Where US 5,455,044 likely fits within that map

Core wedge: method for treating cell proliferative disease via intralumbar CSF delivery of antitumor drug in synthetic membrane vesicles with ventricular persistence.
Narrower wedges: liposome-specific and geometrically defined multi-chamber liposome embodiments.

Practical implications for competitor portfolios

Companies developing intrathecal liposomal cytotoxics typically cluster in:

liposome formulations optimized for CSF distribution
residence-time engineering
sometimes multi-lamellar structures or compartmentalized carriers

Whether they overlap depends on whether their vesicles satisfy the multi-chamber and concentricity/non-concentricity limitations, and whether their use method is intralumbar CSF delivery with sustained ventricular exposure.

How to read the claims for litigation and deal diligence

Claim 1 is the broadest operative protection

It covers any synthetic membrane vesicle system delivering an antitumor drug intralumbar to CSF such that ventricular persistence is achieved.

Key diligence question (in a deal context) is whether a competitor’s regimen:

uses intralumbar injection into CSF
uses a vesicle-based carrier that qualifies as “synthetic membrane vesicle”
achieves sustained ventricular exposure for therapeutic effect

Claims 2-4 constrain device architecture

Claim 2 narrows carrier to liposome.
Claim 3 narrows to multiple concentric chambers.
Claim 4 narrows to multiple non-concentric chambers.

From a portfolio risk standpoint:

A competitor using non-liposome vesicles still faces Claim 1 risk, not Claim 2-4 risk.
A competitor using liposomes with single-lamellar or non-multi-chamber structures may reduce exposure to Claims 3-4, but still face Claim 1-2 if the method and persistence are met.

Key Takeaways

US 5,455,044 claims a method combining intralumbar CSF administration of an antitumor drug delivered in a synthetic membrane vesicle designed to maintain antitumor persistence in the cerebro-ventricular space long enough to ameliorate disease.
Claim 2 limits the carrier to liposomes.
Claims 3 and 4 further limit liposome structure to multiple chambers, split into multiple concentric chambers vs multiple non-concentric chambers.
In the US landscape, the claim sits at the intersection of CSF delivery, liposomal/vesicular encapsulation, and residence-time engineering, with the chamber-geometry features providing narrower fallback protection.

FAQs

1) Does US 5,455,044 claim a specific drug molecule?

No. Claim 1 covers “an antitumor drug” broadly; it is method-scoped by route, carrier type, vesicle nature, and ventricular persistence.

2) Is the patent limited to CNS tumors only?

The claim uses “cell proliferative disease,” not a specific tumor list, so the scope is not limited to a named tumor type by claim text alone.

3) What must be true about the drug after administration?

The antitumor agent must “persist in the cerebro-ventricular space for a time sufficient to ameliorate the disease,” which ties infringement to functional residence in the ventricular region.

4) Do the chamber geometry limitations apply to all claims?

No. Chamber geometry is in dependent claims:

concentric chambers in Claim 3
non-concentric chambers in Claim 4

Claim 1 requires a synthetic membrane vesicle but does not specify concentric or non-concentric chamber geometry.

5) If a competitor uses liposomes but not multi-chamber structures, which claims are most relevant?

Claims most relevant are:

Claim 1 (if the method and persistence are met)
Claim 2 (if the carrier is a liposome) Claims 3 and 4 are specifically about multi-chamber architectures with concentricity distinctions.

References

[No sources cited: none were provided in the prompt.]

Details for Patent: 5,455,044

Summary for Patent: 5,455,044